<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017277</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-22996-24002</org_study_id>
    <secondary_id>EORTC-22996</secondary_id>
    <secondary_id>ARO-EORTC-22996</secondary_id>
    <secondary_id>EORTC-HN-22996</secondary_id>
    <secondary_id>GORTEC-EORTC-22996</secondary_id>
    <secondary_id>TROG-EORTC-22996</secondary_id>
    <secondary_id>RHOG-EORTC-22996</secondary_id>
    <secondary_id>GELCB-EORTC-22996</secondary_id>
    <nct_id>NCT00017277</nct_id>
  </id_info>
  <brief_title>Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer</brief_title>
  <official_title>A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radius Hungaricus Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grup per l'Estudi dels Limfomes de Catalunya i Balears</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may
      help prevent or treat cancer-related anemia. It is not yet known whether radiation therapy is
      more effective with or without epoetin alfa in treating head and neck cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or
      without epoetin alfa in treating patients who have head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of radiotherapy (in terms of local-regional control) with or
           without epoetin alfa in patients with squamous cell carcinoma of the head and neck.

        -  Compare the disease-specific and overall survival of patients treated with these
           regimens.

        -  Compare the hemoglobin level of these patients during radiotherapy.

        -  Compare the acute and late toxic effects of these regimens in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to participating center, site of disease (larynx vs hypopharynx vs
      oropharynx vs oral cavity), T-classification (T1-2 vs T3-4), N-classification and intent of
      systematic neck node dissection (N0-1 vs N2-3 without node dissection vs N2-3 with node
      dissection), hemoglobin level and gender (men with 10-12.5 g/dL vs men with 12.5-14 g/dL vs
      women with 10-12 g/dL vs women with 12-13.5 g/dL), and type of treatment (EORTC standard vs
      other vs randomized in other trials). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients undergo standard radiotherapy 5 days a week and receive concurrent
           epoetin alfa subcutaneously (SC) once weekly.

        -  Arm II: Patients undergo radiotherapy as in arm I and receive concurrent placebo SC once
           weekly.

      Treatment on both arms continues for 6-8 weeks in the absence of disease progression or
      unacceptable toxicity.

      Patients are followed at 3-6 weeks and 9-14 weeks, every 3 months for 2 years, every 6 months
      for 1 year, and then annually thereafter. After any locoregional recurrence, patients are
      followed every 6 months for 1 year and then annually thereafter.

      PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual
  </why_stopped>
  <start_date>March 2001</start_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">47</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell carcinoma of the oral cavity, larynx,
             oropharynx, or hypopharynx

               -  Stage T1-T4, any N

               -  No T1, N0 glottic tumor

               -  No nodal disease from unknown primary

          -  Previously untreated disease

          -  No distant metastases

          -  Planned radiotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 75

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Hemoglobin greater than 10 g/dL but no greater than 14 g/dL for men

          -  Hemoglobin greater than 10 g/dL but no greater than 13.5 g/dL for women

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  No hypertension (diastolic pressure greater than 100 mmHg) refractory to treatment

          -  No symptomatic cardiovascular disease

          -  No deep vein thrombosis

        Other:

          -  No other malignancy except cured basal cell skin cancer or carcinoma in situ of the
             cervix

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance

          -  No smoking during study

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior neoadjuvant chemotherapy

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy to head and neck area

          -  No concurrent nonconventional radiotherapy

        Surgery:

          -  No prior therapeutic surgery to head and neck area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Lambin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Bernier, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jim Denham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Newcastle Mater Misericordiae Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volker G. Budach, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Henri Bourhis, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ferenc Kaldau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radius Hungaricus Oncology Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Sureda</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de la Santa Cruz i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>NSW 2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels (Bruxelles)</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels (Bruxelles)</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Charite</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radius Hungaricus Oncology Group</name>
      <address>
        <city>Torokbalint</city>
        <zip>H-2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiotherapeutisch Instituut Limburg</name>
      <address>
        <city>Heerlen</city>
        <zip>NL-6401 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Cruz I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, Lesaunier F, Benassi T, Lemanski C, Geoffrois L, Lusinchi A, Verrelle P, Bardet E, Julieron M, Wibault P, Luboinski M, Benhamou E. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol. 2006 Jun 20;24(18):2873-8.</citation>
    <PMID>16782926</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

